Portfolio
•
May 27th, 2026

Why we invested in Anodyne Nanotech

HeroPatch delivers multi-milligram doses of biologics and peptides through a pain-free patch, starting with a once-weekly GLP-1 for obesity.

The most exciting drugs of the last decade, from GLP-1s for obesity to monoclonal antibodies, are large molecules. Almost all of them still reach patients by injection. That format shapes everything: whether people keep taking their medicine, how much it costs to ship and store, and how side effects play out. Many patients on GLP-1 therapies stop early. The science has moved on; delivery has not.

HeroPatch, which traces its roots to research at Tufts University, is a patch covered in microscopic, porous polymer microneedles. The drug sits inside the needles in a dry, solid form and is released once the patch is on the skin. Because the delivery system is tuned to the drug rather than the other way round, Anodyne can adjust release profiles, combine multiple drugs in a single patch and keep medicines stable at room temperature, removing much of the cold chain. In large-animal studies, HeroPatch has already delivered clinically relevant GLP-1 doses through the skin.

Delivering multi-milligram doses of large molecules through the skin is a problem many teams have tried and few have solved. Anodyne has the data. Just as important, HeroPatch is a platform rather than a single product. Obesity and cardiometabolic disease are a clear starting point, but the same technology applies to a wide range of injectable therapies where a better patient experience and lifecycle differentiation directly affect pharma economics.

Above all, we invested in the people. The technology began in Professor Sameer Sonkusale's lab at Tufts University, where co-founder Hojat Rezaei Nejad, then a postdoctoral researcher, co-authored award-winning work on low-cost microneedle fabrication. CEO Jake Lombardo, a Tufts engineer with a master's from its Gordon Institute, won the university's New Ventures Competition in 2019, and Chief Business Officer Konstantinos Tzortzakis, an electrical and computer engineer from the National Technical University of Athens, drives the business side. They have shown the discipline to focus the platform where it creates the most value, and we believed they could turn a lab breakthrough into a new standard for drug delivery.